Contribute Try STAT+ Today

Over the past few years, a pack of sleek, marketing-savvy startups have sprouted up offering online prescriptions for drugs for common medical conditions. But even as they’ve touted their rapid growth, they’ve provided few details about their financials — which they’re entitled to do, as privately held companies.

That changed on Thursday, when San Francisco-based Hims & Hers, one of the leaders in the online pharmacy space, filed paperwork with the Securities and Exchange Commission to go public — shining light for the first time on the detailed financials of a business in an emerging sector that’s transformed the way many people get their medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.